natgillin/translations-raw huggingface dataset:
The pharmaceutical composition according to any preceding claim wherein the pharmaceutically acceptable salt of formoterol is selected from hydrochloric, hydrobromic, sulphuric, phosphoric acids, fumaric, maleic, acetic, lactic, citric, tartaric, ascorbic, succinic, glutaric, gluconic, tricarballylic, oleic, benzoic, p-methoxybenzoic, salicylic, o- and p-hydroxybenzoic, p-chlorobenzoic, methanesulfonic, p-toluenesulfonic and 3-hydroxy-2-naphthalene carboxylic acid salts. 
Ko-suspenzija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se farmaceutski prihvatljiva sol formoterola bira između soli klorovodične, bromovodične, sumporne, fosforne, fumarne, maleinske, octene, mliječne, limunske, vinske, askorbinske, jantarne, glutarne, glukonske, trikarbalilne, oleinske, benzojeve, p-metoksibenzojeve, salicilne, o- i p-hidroksibenzojeve, p-klorbenzojeve, metansulfonske, p-toluensulfonske i 3-hidroksi-2-naftalenkarboksilne kiseline.
A composition for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer, said composition comprising an excipient and a therapeutically effective amount of the compound or therapeutically acceptable salt of claim 1 or 2. 
Spoj za uporabu u liječenju bolesti iz skupine koju čine rak mokraćnog mjehura, rak mozga, rak dojke, rak koštane srži, cervikalni rak, kronična limfocitna leukemija, rak debelog crijeva, rak jednjaka, rak jetre, limfoblastična leukemija, folikularni limfomi, limfna malignost uzorkovana T-stanicama ili B-stanicama, melanom, mijeloične leukemije, mijeloma, oralni karcinom, rak jajnika, rak ne-malih stanica pluća, rak prostate, rak malih stanica pluća ili rak slezene, naznačen time, da navedeni pripravak sadržava pomoćno sredstvo i terapeutski djelotvornu količinu spoja ili terapeutski prihvatljive soli u skladu s bilo kojim od patentnih zahtjeva 1 do 13.
The compound or therapeutically acceptable salt of claim 1 or 2 for use in treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient. 
Spoj ili terapeutski prihvatljiva sol u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time, da se rabi u liječenju sljedećih bolesti kod pacijenta: rak mokraćnog mjehura, rak mozga, rak dojke, rak koštane srži, cervikalni rak, kronična limfocitna leukemija, rak debelog crijeva, rak jednjaka, rak jetre, limfoblastična leukemija, folikularni limfomi, limfna malignost uzrokovana T-stanicama ili B-stanicama, melanom, mijeloične leukemije, mijeloma, oralni karcinom, rak jajnika, rak ne-malih stanica pluća, rak prostate, rak malih stanica pluća ili rak slezene.
A composition comprising desmopressin for use in treating a female patient having nocturia or nocturnal polyuria, by reducing nocturnal urine volume in the female patient in need thereof, the composition comprising an orodispersible dose of desmopressin of 25 µg for administration prior to bedtime, wherein the dose is measured as the free base of desmopressin. 
Pripravak, koji sadrži dezmopresin za uporabu kod liječenja nokturije ili noćne poliurije, za smanjenje broja noćnih pražnjenja mjehura kod pacijentice, koja treba takvo liječenje, te pripravak sadrži orodisperzibilnu dozu dezmopresina u količini od 25 µg za administraciju prije počinka, naznačen time da se doza mjeri kao slobodna baza dezmopresina.
A composition for use according to claim 1 for reducing nocturnal urine volume in a female patient above 50 years of age. 
Pripravak za uporabu prema zahtjevu 1 naznačen time da je za liječenje pacijentice starije od 50 godina.
subjecting the compound of formula (4) to Smile's rearrangement in the presence of bases, so as to obtain the final compound of formula (5) 
podvrgavanje spoja s formulom (4) Smile-ovom premještanju u prisutnosti baza, tako da se dobije konačni spoj formule (5) [image]
A process for the preparation of iopamidol according to claim 11 wherein, within the compounds of formula from (1) to (5), R and R' both represent a -CONH-CH(CH2OH)2 group, R4 is hydrogen and R5 is methyl. 
Postupak prema zahtjevima 10 ili 11 naznačen time da je za pripremanje spoja s formulom (5) pri čemu oba R i R' su skupina -CONH-CH(CH2OH)2, R4 je vodik i R5 je metil.
A process for the preparation of iomeprol according to claim 11 wherein, within the compounds of formula from (1) to (5), R and R' both represent a CONH-CH2(CHOH)CH2OH group, R4 is methyl and R5 is hydrogen. 
Postupak prema zahtjevima 10 ili 11 naznačen time da je za pripremanje spoja s formulom (5) pri čemu oba R i R' predstavljaju skupinu -CONH-CH2-CH(OH)CH2OH, R4 je metil i R5 je vodik.
The pharmaceutical composition for oral administration according to claim 1, wherein the immediate release portion is disintegrated and/or dissolved before the modified release portion forms a gel. 
Tableta za oralnu primjenu prema zahtjevu 1, gdje se dio s trenutnim otpuštanjem raspada i/ili otapa prije nego što dio s prilagođenim oslobađanjem formira gel.
The pharmaceutical composition for oral administration according to claim 1 or 2, wherein 70% or more of solifenacin, is dissolved for 15 minutes. 
Tableta za oralnu primjenu prema zahtjevu 1 ili 2, gdje se 85% ili više solifenacina otpušta nakon 15 minuta.
The pharmaceutical composition for oral administration according to claim 3, wherein 90% or more of solifenacin is dissolved for 60 minutes. 
Tableta za oralnu primjenu prema zahtjevu 3, gdje 90% ili više solifenacina otpušta nakon 60 minuta.
The pharmaceutical composition for oral administration according to claim 5, wherein 85% or more of solifenacin is dissolved for 30 minutes and 90% or more of solifenacin is dissolved for 60 minutes. 
Tableta za oralnu primjenu prema zahtjevu 3, gdje se 85% ili više solifenacina otpušta nakon 30 minuta i 90% ili više solifenacina se otpušta nakon 60 minuta.
The pharmaceutical composition for oral administration according to claim 17, wherein the additive which allows water to penetrate into the formulation has a solubility such that the amount of water necessary to dissolve 1 g of the additive is 5 mL or less. 
Tableta za oralnu primjenu prema zahtjevu 15, gdje aditiv koji omogućuje penetraciju vode u oblik ima topljivost takvu da količina vode koja je potrebna za otapanje 1 g aditiva iznosi 5 ml ili manje.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of hepatocellular carcinoma and cholangiocarcinoma according to claim 1, characterized in that nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof is/are formulated for oral, parenteral, subcutaneous, intravenous, intramuscular, nasal, topical or rectal administration. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koja/koje se upotrebljava(ju) u liječenju i/ili prevenciji autoimunog hepatitisa prema zahtjevu 1, naznačena/e time, da se nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, formulira(ju) za oralnu, parenteralnu, subkutanu, intravenoznu, intramuskularnu, nazalnu, topikalnu ili rektalnu primjenu.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of hepatocellular carcinoma and cholangiocarcinoma according to claims 1 or 2, characterized in that nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof is/are to be administered to a patient in an amount of 25 mg to 5 g, preferably 100 mg to 2,5 g, in particular 800 mg to 1,5 g per day. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koja/koje se upotrebljava(ju) u liječenju i/ili prevenciji autoimunog hepatitisa prema zahtjevima 1 ili 2, naznačena/e time, da se nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, treba(ju) davati pacijentu u dnevnoj količini od 25 mg do 5 g, poželjno od 100 mg do 2,5 g, posebno od 800 mg do 1,5 g.
A pharmaceutical composition according to claim 15 for use in the treatment or prevention of a metabolic disorder in a human. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 15, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju metaboličkog poremećaja kod čovjeka.
The use of a compound or salt as for use according to claim 17 wherein said metabolic disorder is diabetes mellitus (Type I and Type II) or obesity. 
Upotreba spoja ili soli, kao prilikom upotrebe u skladu s patentnim zahtjevom 17, naznačena time što je navedeni metabolički poremećaj dijabetes melitus (tip I i tip II) ili pretilost.
The use of a compound or salt as defined in any of claims 1-14 in the manufacture of a medicament for the treatment or prevention of a metabolic disorder in a human. 
Upotreba spoja ili soli u skladu s bilo kojim od patentnim zahtjevima 1-14, naznačena time što su spoj ili sol namijenjeni proizvodnji medikamenta za liječenje ili sprječavanje metaboličkog poremećaja kod čovjeka.
Use of ethylenediamine tetraacetic acid or a salt thereof acceptable for animal health care purposes for preparing an agent for the prevention and/or treatment of pig dysentery caused by Brachyspira hyodysenteriae. 
Uporaba etilendiamino tetraoctene kiseline (EDTA) ili njezinih soli prikladnih za zdravstvenu njegu životinja za pripremu sredstva za prevenciju i/ili liječenje dizenterije svinja uzrokovane s Brachyspira hyodysenteriae.
Use of ethylenediamine tetraacetic acid or a salt thereof according to claim 1 acceptable for animal health care purposes for preparing in combination with antibiotics an agent for the treatment of pig dysentery caused by Brachyspira hyodysenteriae. 
Uporaba etilendiamino tetraoctene kiseline (EDTA) ili njezinih soli prema zahtjevu 1 prikladnih za zdravstvenu njegu životinja za pripremu, u kombinaciji s antibioticima, sredstva za liječenje dizenterije svinja uzrokovane s Brachyspira hyodysenteriae.
Ethylenediamine tetraacetic acid or a salt thereof acceptable for animal health care for use in the prevention and/or treatment of pig dysentery caused by Brachyspira hyodysenteriae. 
Etilendiamino tetraoctena kiselina ili njezina sol prikladna za zdravstvenu njegu životinja za uporabu u prevenciji i/ili liječenju dizenterije svinja uzrokovane s Brachyspira hyodysenteriae.
Ethylenediamine tetraacetic acid or a salt thereof for use according to claim 3 in a veterinary composition. 
Etilendiamino tetraoctena kiselina ili njezina sol za uporabu prema zahtjevu 3 u veterinarskom pripravku.
Ethylenediamine tetraacetic acid or a salt thereof for use according to claim 3 in a fodder, a feed, a nourishment, a premix or a suspension. 
Etilendiamino tetraoctena kiselina ili njezina sol za uporabu prema zahtjevu 3 u stočnoj hrani, prehrani, dodacima prehrani, predsmjesi ili suspenziji.
Ethylenediamine tetraacetic acid or a salt thereof for use according to any one of claims 3 to 5 in a fodder for direct consumption which comprises for 1 ton of fodder 30-720 g of ethylenediamine tetraacetic acid or an equivalent amount of ethylenediamine tetraacetic acid salt. 
Etilendiamino tetraoctena kiselina ili njezina sol za uporabu prema bilo kojem od zahtjeva 3 do 5 u stočnoj hrani za izravnu konzumaciju koja sadrži na 1 tonu stočne hrane 30-720 g etilendiamino tetraoctene kiseline ili ili ekvivalentnu količinu soli etilendiamino tetraoctene kiseline.
Ethylenediamine tetraacetic acid or a salt thereof for use according to claim 6 in a composition comprising for 1 ton of fodder 150-350 g of ethylenediamine tetraacetic acid or an equivalent amount of ethylenediamine tetraacetic acid salt. 
Etilendiamino tetraoctena kiselina ili njezina sol za uporabu prema zahtjevu 6 u pripravku koji sadrži na 1 tonu stočne hrane 150-350 g etilendiamino tetraoctene kiseline ili ekvivalentnu količinu soli etilendiamino tetraoctene kiseline.
Ethylenediamine tetraacetic acid or a salt thereof for use according to claim 9, wherein the activity-complementing agent is an essential oil acceptable for animal health care, tannic acid and/or lysozyme enzyme. 
Etilendiamino tetraoctena kiselina ili njezina sol za uporabu prema zahtjevu 9, gdje je sredstvo koje nadopunjava djelovanje esencijalno ulje prikladno za zdravstvenu njegu životinja, taninska kiselina i/ili lizozimski enzim.
Ethylenediamine tetraacetic acid or a salt thereof for use according to any one of claims 3, 5 and 6, in combination with an antibiotic applicable for the treatment of bacterial intestinal diseases in pigs. 
Etilendiamino tetraoctena kiselina ili njezina sol za uporabu prema bilo kojem od zahtjeva 3, 5 i 6, u kombinaciji s antibiotikom primjenjivim za liječenje bakterijskih intestinalnih bolesti u svinja.
Ethylenediamine tetraacetic acid or a salt thereof for use according to claim 11, wherein the antibiotic is lincomycin or thiamulin. 
Etilendiamino tetraoctena kiselina ili njezina sol za uporabu prema zahtjevu 11, gdje je antibiotik linkomicin ili tiamulin.
Ethylenediamine tetraacetic acid or a salt thereof for use according to claim 3 in drinking water or a drinking water additive. 
Etilendiamino tetraoctena kiselina ili njezina sol za uporabu prema zahtjevu 3 u pitkoj vodi ili dodatku za pitku vodu.
Ethylenediamine tetraacetic acid or a salt thereof for use according to claim 13 or 14 in drinking water at a concentration in the range from 10-350 grams of ethylenediamine tetraacetic acid, or an equivalent amounts of an ethylenediamine tetraacetic acid salt, per 1000 litres drinking water. 
Etilendiamino tetraoctena kiselina ili njezina sol za uporabu prema zahtjevu 13 ili 14 u pitkoj vodi u koncentraciji u rasponu od 10-350 grama etilendiamino tetraoctene kiseline, ili ekvivalentna količina soli etilendiamino tetraoctene kiseline, na 1000 litara pitke vode.
Tapentadol for use in the treatment of irritable bowel syndrome. 
Tapentadol naznačen time da je za uporabu u liječenju sindroma iritabilnog crijeva.
Tapentadol for use according to claim 1, wherein irritable bowel syndrome is selected from the group consisting of irritable bowel syndrome with diarrhea, diarrhea-predominant irritable bowel syndrome, irritable bowel syndrome without diarrhea, constipation-predominant irritable bowel syndrome, irritable bowel syndrome with alternating stool pattern (irritable bowel syndrome with alternating constipation and diarrhea, mixed irritable bowel syndrome) and post infectious irritable bowel syndrome. 
Tapentadol za uporabu prema zahtjevu 1, naznačen time da je sindrom iritabilnog crijeva odabran iz skupine koja sadrži sindrom iritabilnog crijeva s proljevom, sindrom iritabilnog crijeva s prevladavajućim proljevom, sindrom iritabilnog crijeva bez proljeva, sindrom iritabilnog crijeva s prevladavajućom konstipacijom, sindrom iritabilnog crijeva s naizmjeničnim uzorkom stolice (sindrom iritabilnog crijeva s naizmjeničnom konstipacijom i proljevom, mješoviti sindrom iritabilnog crijeva) i post infektivni sindrom iritabilnog crijeva.
Tapentadol for use according to claim 1 or 2, wherein it is present in a medicament. 
Tapentadol za uporabu prema zahtjevu 1 ili 2, naznačen time da se nalazi u lijeku.
The solid state form according to Claim 2, which is the free base of N-((S)-2,3-Dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide. 
Oblik u krutom stanju prema zahtjevu 2, naznačen time da je slobodna baza od N-((S)-2,3-dihidroksi-propil)-3-(2-fluoro-4-jodo-fenilamino)-izonikotinamida.
Use of a pharmaceutical composition according to claim 37 in the manufacture of medicaments for use as pro-apoptotic agents. 
Uporaba farmaceutskog pripravka u skladu s patentnim zahtjevom 37, naznačena time, da je za proizvodnju lijekova za uporabu kao proapoptotičko sredstvo.
Use of a pharmaceutical composition according to claim 37 in the manufacture of medicaments for use in the treatment of cancers and of auto-immune and immune system diseases. 
Uporaba farmaceutskog pripravka u skladu s patentnim zahtjevom 37, naznačena time, da je za proizvodnju lijekova za uporabu u liječenju karcinoma i auto-imunih bolesti te bolesti imuno-sustava.
Combination according to claim 46 for use in the treatment of cancers. 
Kombinacija u skladu s patentnim zahtjevom 46, naznačena time, da je za uporabu u liječenju karcinoma.
Use of a combination according to claim 46 in the manufacture of medicaments for use in the treatment of cancers. 
Uporaba kombinacije u skladu s patentnim zahtjevom 46, naznačen time, da je ista za proizvodnju lijekova za uporabu u liječenju karcinoma.
A method for the production of a solid bio-product wherein at least 80 % of the original indigestible oligosaccharide content has been degraded into digestible mono- and disaccharides, comprising the following steps: 
Postupak za proizvodnju krutog bio-proizvoda pri čemu je barem 80 % izvornog neprobavljivog sadržaja oligosaharida degradirano u probavljive mono- i disaharide, naznačen time da sadrži slijedeće korake:
reacting the mixture resulting from step (1) under continuous mixing and under conditions where the water content in the initial mixture does not exceed 65 % by weight, for 0.15-36 hours at a temperature of about 20-65°C; 
reakciju smjese nastale u koraku (1) uz stalno miješanje i pod uvjetima gdje udio vode u početnoj smjesi ne prelazi 65 % težinski, tijekom 0.15-36 sati na temperaturi od oko 20-65°C;
incubating the reacted mixture from step (2) at a temperature and in a time period which inactivate said a-galactosidase(s). 
inkubiranje reagirane smjese iz koraka (2) na temperaturi i tijekom vremenskog perioda koji deaktivira navedenu a-galaktozidazu(e).
Method according to claim 1 further comprising that fungus and/or bacteria is added to said biomass in an amount that results in a dry matter ratio of fungus/bacteria to said biomass of from 1:2 to 1:400, wherein said incubating in step (3) is carried out at a temperature and in a time period which inactivate said a-galactosidase(s) and fungus and/or bacteria. 
Postupak prema zahtjevu 1, naznačen time da dodatno obuhvaća da se gljivica i/ili bakterija dodaje u navedenu biomasu u količini koja rezultira s omjerom suhe tvari gljivice/bakterije prema navedenoj biomasi od 1:2 do 1:400, pri čemu se navedena inkubacija u koraku (3) provodi na temperaturi i tijekom vremenskog perioda koji deaktivira navedenu a-galaktozidazu(e) i gljivicu i/ili bakteriju.
Method according to any one of claims 1-4, further comprising that said reaction in step (2) is performed in one or more non-vertical, interconnected paddle worm or continuous worm conveyers with inlet means for the reaction mixture and additives and outlet means for the product as well as control means for rotation speed, temperature and pH or in a Vertical Screw Mixer, e.g. a Nauta Mixer. 
Postupak prema bilo kojem od zahtjeva 1-4, naznačen time da dodatno obuhvaća da se navedena reakcija u koraku (2) provodi u jednom ili više ne-vertikalnih, međusobno povezanih pužnih transportera s lopaticama ili kontinuiranih pužnih transportera sa sredstvima za dovod za reakcijsku smjesu i dodatke i sredstvima za izlaz za proizvod kao i kontrolnim sredstvima za brzinu rotacije, temperaturu i pH ili u okomitoj pužnoj mješalici, npr.
Method according to any one of claims 2-7, wherein said fungus and/or bacteria is live yeast selected among Saccharomyces cerevisiae strains, including spent brewer's yeast and spent distiller's yeast and spent yeast from wine production and baker's yeast, as well as yeast strains fermenting C5 sugars. 
Postupak prema bilo kojem od zahtjeva 2-7, naznačen time da navedena gljivica i/ili bakterija je aktivni kvasac koji se bira između soja Saccharomyces cerevisiae, uključujući pivski kvasac i destilacijski kvasac i kvasac iz proizvodnje vina i pekarski kvasac, kao i sojeve kvasaca fermentirajućih C5 šećera.
Method according to any one of the preceding claims where said proteinaceous plant parts is pulses, such as soy, bean, pea, lupine, and/or cereals, such as wheat, and/or seeds, such as rape seed, and/or grasses which plant parts may be defatted. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da navedeni dijelovi proteinskih biljaka su mahunarke, kao što su soja, grah, grašak, vučika, i/ili žitarice, kao što je pšenica, i/ili sjeme, kao što je uljana repica, i/ili trave navedeni dijelovi biljke mogu biti oslobođeni masti.
from seeds of oil bearing plants, e.g. 
iz sjemenki uljarica, npr.
rape seed and soy. 
uljane repice i soje.
Solid bio-product according to claim 20 comprising plant proteins in an amount of less than about 60 % by weight. 
Kruti bio-proizvod prema zahtjevu 20, naznačen time da sadrži biljne proteine u količini manjoj od oko 60 % težinski.
less than 5 % by weight or less than 2 % by weight. 
manja od 5 % težinski ili manja od 2 % težinski.
A food, feed, cosmetic or pharmaceutical product or a nutritional supplement containing from 1 to 99% by weight of a solid bio-product according to any one of claims 19-25. 
Hrana, prehrambeni proizvod, kozmetički ili farmaceutski proizvod ili prehrambeni dodatak, naznačen time da sadrži od 1 do 99% težinski krutog bio-proizvoda prema bilo kojem od zahtjeva 19-25.
a plurality of active agent particles comprising an active agent selected from glycopyrrolate and formoterol and any pharmaceutically acceptable salts, esters, enantiomers, mixtures of enantiomers or solvates thereof; and a plurality of respirable suspending particles which are perforated microstructures comprising DSPC (1,2-disteroyl-sn-glycero-3-phosphocholine) and calcium chloride, and wherein the plurality of active agent particles co-locate with the plurality of suspending particles within the suspension medium to form a co-suspension. 
više čestica aktivnog sredstva koje sadrže aktivno sredstvo koje se bira između glikopirolata i formoterola i bilo kojih farmaceutski prihvatljivih soli, estera, enantiomera, smjesa njihovih enantiomera ili solvata; i više suspendirajućih čestica pogodnih za unos u dišne puteve, koje su perforirane mikrostrukture koje sadrže DSPC (1,2-disteroil-sn-glicero-3-fosfokolin) i kalcijev klorid, te gdje su više čestica aktivnog sredstva ko-locirane s više suspendirajućih čestica u suspenzijskom mediju kako bi tvorile ko-suspenziju.
The pharmaceutical composition according to claim 1 wherein the perforated microstructures comprise a spray-dried emulsion of perfluorooctyl bromide, DSPC and calcium chloride in water. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što perforirane mikrostrukture sadrže emulziju perfluoroktil-bromida, DSPC i kalcijevog klorida u vodi osušenu raspršivanjem.
The pharmaceutical composition according to claim 16 wherein the pharmaceutically acceptable salt of formoterol is selected from hydrochloric, hydrobromic, sulphuric, phosphoric acids, fumaric, maleic, acetic, lactic, citric, tartaric, ascorbic, succinic, glutaric, gluconic, tricarballylic, oleic, benzoic, p-methoxybenzoic, salicylic, o- and p-hydroxybenzoic, p-chlorobenzoic, methanesulfonic, p-toluenesulfonic and 3-hydroxy-2-naphthalene carboxylic acid salts. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 16, naznačen time što se farmaceutski prihvatljiva sol formoterola bira između soli klorovodične, bromovodične, sumporne, fosforne, fumarne, maleinske, octene, mliječne, limunske, vinske, askorbinske, jantarne, glutarne, glukonske, trikarbalilne, oleinske, benzojeve, p-metoksibenzojeve, saliciline, o- i p-hidroksibenzojeve, p-klorbenzojeve, metansulfonske, p-toluensulfonske i 3-hidroksi-2-naftalenkarboksilne kiseline.